CTOs on the Move


 
Developing breakthrough medicines for patients with cancer and rare genetic diseases is incredibly important, and so difficult. It takes great science. But it also takes an environment where people care – about the work, about each other, and about patients. At Agios, we`re always looking for the sweet spot between exhilaration and anxiety – while being respectful, kind and connected with each other so we can flourish. At our core, we`re a biopharmaceutical company passionately committed to applying our scientific leadership in the field of cellular metabolism to transform the lives of patients. We`re a science-driven, global organization that`s built ...
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.agios.com
  • 88 Sidney Street
    Cambridge, MA USA 02139
  • Phone: 617.649.8600

Executives

Name Title Contact Details

Similar Companies

Homecure

Homecure is a Tempe, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

InSightec

InSightec is the world leader and innovator of MR-guided Focused Ultrasound (MRgFUS). The company`s non-invasive therapy platforms, Exablate and Exablate Neuro, are proven technology based on sound clinical evidence for treating essential tremor, painful bone metastases and uterine fibroids. The company is dedicated to improving patient lives by collaborating with physicians, medical institutions, academic researchers and regulatory bodies around the world.

Alpha Genesis

Alpha Genesis is a Yemassee, SC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

SK Life Sciences

SK Life Sciences is a Fair Lawn, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Galmed Pharmaceuticals

Galmed Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of Aramchol, a novel, once-daily, oral therapy for treating liver diseases utilizing its proprietary first-in-class family of synthetic fatty-acid/bile-acid conjugates, or FABACs. Aramchol is initially being developed for treating Non-Alcoholic Steato-hepatitis, or NASH, a chronic disease affecting a large population, for treating patients who also suffer from obesity and insulin resistance. Galmed Pharmaceuticals Galmed’s business has been, in its current legal structure, was incorporated in Israel on July 31, 2013 as a privately held company. However, operating since 2000 under a different group of companies established in the same year. Galmed was co-founded by Professor Tuvia Gilat and Allen Baharaff, based on Professor Gilat’s extensive research in FABAC’s and NASH.